Morgan Stanley

Barclays analyst Jason Goldberg maintains Morgan Stanley (NYSE:MS) with a Overweight and raises the price target from $102 to $116.

CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: As a leading global investment bank, we think MS is poised to benefit from a potential rebound in M&A and debt/equity underwriting in the year ahead. We raise our 12-month target $15 to $105 on a forward P/E of 14.8x our 2024 earnings estimate, above the three-year historic average at 13.0x given our view of a cyclical rebound in MS’s businesses. We keep our earnings estimates for 2023 at $5.90 and 2024 at $7.10, both above consensus at $5.61 and $6.59. Even during a risk-off market, we think MS gained wallet share in the past year, with several European banks having retrenched from investment banking. The Fed’s signal of potential rate cuts in 2024 is likely to get corporates positioned for higher capital raising, debt refinancing, and

Goldman Sachs analyst Richard Ramsden maintains Morgan Stanley (NYSE:MS) with a Buy and raises the price target from $89 to $100.

Morgan Stanley (NYSE:MS) Stock Analyst Ratings Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 12/19/2023 9.59% Goldman Sachs $89 → $100 Maintains Buy 11/28/2023 -12.33% Societe Generale → $80 Downgrades Buy → Hold 11/20/2023 -6.85% Exane BNP Paribas → $85 Downgrades Outperform → Neutral 11/16/2023 12.88% Oppenheimer $98 → $103 Maintains Outperform 10/23/2023 -13.26% Odeon Capital → $79.15 Downgrades Buy → Hold 10/20/2023 — Wolfe Research Upgrades Underperform → Peer Perform 10/19/2023 6.3% Evercore ISI Group $102 → $97 Maintains Outperform 10/19/2023 10.68% BMO Capital $102 → $101 Maintains Outperform 10/19/2023 7.4% Oppenheimer $100 → $98 Maintains Outperform 10/11/2023 -7.95% UBS $110 → $84 Downgrades Buy → Neutral 10/05/2023 0.82% JP Morgan $93 → $92 Maintains Overweight 09/26/2023 9.59% Oppenheimer $105 → $100 Maintains Outperform 09/25/2023 -1.37% RBC Capital → $90 Reiterates Sector Perform → Sector Perform 09/07/2023 8.49% HSBC → $99 Initiates Coverage On

Morgan Stanley (NYSE:MS) Analyst Ratings Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 11/28/2023 3.21% Societe Generale → $80 Downgrades Buy → Hold 11/20/2023 9.66% Exane BNP Paribas → $85 Downgrades Outperform → Neutral 11/16/2023 32.89% Oppenheimer $98 → $103 Maintains Outperform 10/23/2023 2.12% Odeon Capital → $79.15 Downgrades Buy → Hold 10/20/2023 — Wolfe Research Upgrades Underperform → Peer Perform 10/19/2023 25.15% Evercore ISI Group $102 → $97 Maintains Outperform 10/19/2023 30.31% BMO Capital $102 → $101 Maintains Outperform 10/19/2023 26.44% Oppenheimer $100 → $98 Maintains Outperform 10/11/2023 8.37% UBS $110 → $84 Downgrades Buy → Neutral 10/05/2023 18.69% JP Morgan $93 → $92 Maintains Overweight 09/26/2023 29.02% Oppenheimer $105 → $100 Maintains Outperform 09/25/2023 16.11% RBC Capital → $90 Reiterates Sector Perform → Sector Perform 09/07/2023 27.73% HSBC → $99 Initiates Coverage On → Buy 08/18/2023 35.47% Oppenheimer $110 → $105 Maintains Outperform

Oppenheimer analyst Chris Kotowski maintains Morgan Stanley (NYSE:MS) with a Outperform and lowers the price target from $100 to $98.

CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: MS results highlight doldrums in the capital markets with lower market volatility and less risk-taking by investors. We lower our target price by $6 to $90 on forward P/E of 12.7x, which reflects a hybrid valuation of part investment bank and part asset/wealth management firm. We keep our 2023 EPS at $5.90 and 2024’s at $7.10. MS posted Q3 2023 EPS of $1.39, a $0.07 consensus beat. Wealth Management unit realized -4% revenue decline Y/Y (48% of Q3 2023 revenue), with Investment Management +14% (10%) and Institutional Securities -3% (42%). Investment banking realized lower M&A fees (-1% Y/Y), debt underwriting -36% due to lower event-driven high-yield activity and muted equity underwriting +5%. Equity trading was -2% and FICC +13%. America’s revenue was -1% Y/Y (77% of total),

Morgan Stanley Third Quarter 2023 Earnings Results Morgan Stanley Reports Net Revenues of $13.3 Billion, EPS of $1.38 and ROTCE of 13.5% NEW YORK—-October 18, 2023– Morgan Stanley (NYSE: MS) today reported net revenues of $13.3 billion for the third quarter ended September 30, 2023 compared to $13.0 billion a year ago. Net income applicable to Morgan Stanley was $2.4 billion, or $1.38 per diluted share,(1) compared to net income of $2.6 billion, or $1.47 per diluted share,(1) for the same period a year ago. James P. Gorman, Chairman and Chief Executive Officer, said, “While the market environment remained mixed this quarter, the Firm delivered solid results with an ROTCE of 13.5%. Our Equity and Fixed Income businesses navigated markets well, and both Wealth and Investment Management produced higher revenues and profits year-over-year. We completed the integration of E*TRADE in the quarter, further executing on our strategy of building revenue

Morgan Stanley Q3 EPS $1.38 Vs. $1.47 a Year Ago, Beats the FactSet Consensus $1.31。

MORGAN STANLEY Posts Q3 Revenue $13.27B, vs. Street Est of $13.22B。

UBS analyst Brennan Hawken downgrades Morgan Stanley (NYSE:MS) from Buy to Neutral and lowers the price target from $110 to $84.